The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumResearch - Investors who were involved for the now-failed Alzheimer’s program are vacating the stock. That’s an opportunity for new investors, like us, looking further down the road to what could be a compelling and novel diabetes treatment.
PremiumzPremium - Greece unknowns weigh on the market going into the holiday weekend (Happy fourth by the way!), but the referendum on Sunday should offer some perspective … Continue Reading
PremiumInsights - Celgene (CELG) has placed its bet in the race to develop and market T cell therapies for oncology with a $1 billion infusion in cell therapy … Continue Reading
Read nowInsights - That’s a bit disingenuous, but Seres Health’s (MCRB) SER-109 isn’t far from it. The company made a splash on Friday when it IPO’d at $18, and … Continue Reading
Read nowInsights - It’s one of the most elusive events in biotech: the liquidation. But after a trial failure of epic proportions – and a collapse in its stock … Continue Reading
Read nowInsights - Two drugs directed at behavioral disorders failed mid-stage studies on Wednesday morning, said sponsors Alcobra (ADHD) and Transition Therapeutics (TTHI), yet again highlighting the difficulty in developing drugs for disorders involving the Central Nervous System.
Read nowInsights - Disparate results from two gene therapy developers are worth a mention in this week’s biotech recap. Avalanche Biotechnologies (AAVL) blew up spectacularly this Monday with … Continue Reading
Read now
